Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE-DOSE TOPICAL ADMINISTRATION OF PF-07905428 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ACNE VULGARIS, AND ADDITIONALLY CLINICAL EFFECT IN PARTICIPANTS WITH MODERATE TO SEVERE ACNE VULGARIS AGED 18 TO 40 YEARS OLD

NCT06671834 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06671834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06671834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE-DOSE TOPICAL ADMINISTRATION OF PF-07905428 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ACNE VULGARIS, AND ADDITIONALLY CLINICAL EFFECT IN PARTICIPANTS WITH MODERATE TO SEVERE ACNE VULGARIS AGED 18 TO 40 YEARS OLD
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
November 22, 2024
Completion date
December 4, 2025
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris